Little Polymorphism at the K13 Propeller Locus in Worldwide Plasmodium falciparum Populations Prior to the Introduction of Artemisinin Combination Therapies

Antimicrob Agents Chemother. 2016 May 23;60(6):3340-7. doi: 10.1128/AAC.02370-15. Print 2016 Jun.

Abstract

The emergence and spread of artemisinin-resistant Plasmodium falciparum is of huge concern for the global effort toward malaria control and elimination. Artemisinin resistance, defined as a delayed time to parasite clearance following administration of artemisinin, is associated with mutations in the Pfkelch13 gene of resistant parasites. To date, as many as 60 nonsynonymous mutations have been identified in this gene, but whether these mutations have been selected by artemisinin usage or merely reflect natural polymorphism independent of selection is currently unknown. To clarify this, we sequenced the Pfkelch13 propeller domain in 581 isolates collected before (420 isolates) and after (161 isolates) the implementation of artemisinin combination therapies (ACTs), from various regions of endemicity worldwide. Nonsynonymous mutations were observed in 1% of parasites isolated prior to the introduction of ACTs. Frequencies of mutant isolates, nucleotide diversity, and haplotype diversity were significantly higher in the parasites isolated from populations exposed to artemisinin than in those from populations that had not been exposed to the drug. In the artemisinin-exposed population, a significant excess of dN compared to dS was observed, suggesting the presence of positive selection. In contrast, pairwise comparison of dN and dS and the McDonald and Kreitman test indicate that purifying selection acts on the Pfkelch13 propeller domain in populations not exposed to ACTs. These population genetic analyses reveal a low baseline of Pfkelch13 polymorphism, probably due to purifying selection in the absence of artemisinin selection. In contrast, various Pfkelch13 mutations have been selected under artemisinin pressure.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimalarials / pharmacology*
  • Artemisinins / pharmacology*
  • Genetics, Population
  • Humans
  • Malaria, Falciparum / parasitology
  • Mutation / genetics
  • Plasmodium falciparum / drug effects
  • Plasmodium falciparum / genetics*
  • Polymorphism, Genetic / genetics*

Substances

  • Antimalarials
  • Artemisinins

Grants and funding

This work, including the efforts of Toshihiro Mita, was funded by Cooperative Research Grants of NEKKEN, Japan (25-Ippan-05 and 26-Ippan-11), the Foundation of Strategic Research Projects in Private Universities (S0991013), grants-in-aid from scientific research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (23659211 and 23590498), and Health and Labour Science Research Grants from Ministry of Health Labour and Welfare, Japan (H26-Iryokiki-Ippan-004). This work, including the efforts of Marcelo U. Ferreira, was funded by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (grant 98/14587-1).